参考文献/References:
[1] Joffre J,Potteaux S,Zeboudj L,et al. Genetic and pharmacological inhibition of TREM-1 limits the development of experimental atherosclerosis[J]. J Am Coll Cardiol,2016,68(25):2776-2793.
[2] Wang F,Li C,Ding FH,et al. Increased serum TREM-1 level is associated with in-stent restenosis,and activation of TREM-1 promotes inflammation,proliferation and migration in vascular smooth muscle cells[J]. Atherosclerosis,2017,267:10-18.
[3] Gibot S,Jolly L,Lemarié J,et al. Triggering receptor expressed on myeloid cells-1 inhibitor targeted to endothelium decreases cell activation[J]. Front Immunol,2019,10:2314.
[4] Carrasco K,Boufenzer A,Jolly L,et al. TREM-1 multimerization is essential for its activation on monocytes and neutrophils[J]. Cell Mol Immunol,2019,16(5):460-472.
[5] Tammaro A,Derive M,Gibot S,et al. TREM-1 and its potential ligands in non-infectious diseases:from biology to clinical perspectives[J]. Pharmacol Ther,2017,177:81-95.
[6] Jolly L,Carrasco K,Salcedo-Magguilli M,et al. sTREM-1 is a specific biomarker of TREM-1 pathway activation[J]. Cell Mol Immunol,2021,18(8):2054-2056.
[7] Wright S,Lovelace-Macon L,Hantrakun V,et al. sTREM-1 predicts mortality in hospitalized patients with infection in a tropical,middle-income country[J]. BMC Med,2020,18(1):159.
[8] Kung C,Su C,Hsiao S,et al. The prognostic value of serum soluble TREM-1 on outcome in adult patients with sepsis[J]. Diagnostics (Basel). 2021 Oct 25;11(11):1979.
[9] de Nooijer A,Grondman I,Lambden S,et al. Increased sTREM-1 plasma concentrations are associated with poor clinical outcomes in patients with COVID-19[J]. Biosci Rep,2021,41(7):BSR20210940.
[10] Boufenzer A,Lemarié J,Simon T,et al. TREM-1 mediates inflammatory injury and cardiac remodeling following myocardial infarction[J]. Circ Res,2015,116(11):1772-1782.
[11] Thankam FG,Sanchez DJ,Agrawal DK. Design of the lentivirus-driven sustained LR12 delivery system for TREM-1 inhibition for palliating atherosclerosis[J]. Mol Cell Biochem,2022,477(3):701-710.
[12] Shi W,Sun Y,Wang J,et al. Trem1 mediates neuronal apoptosis via interaction with SYK after spinal cord ischemia-reperfusion injury[J]. Am J Transl Res,2021,13(6):6117-6125.
[13] Pan P,Liu X,Wu L,et al. TREM-1 promoted apoptosis and inhibited autophagy in LPS-treated HK-2 cells through the NF-κB pathway[J]. Int J Med Sci,2021,18(1):8-17.
[14] Xie Y,Li X,Lv D,et al. TREM-1 amplifies trophoblastic inflammation via activating NF-κB pathway during preeclampsia[J]. Placenta,2021,115:97-105.
[15] Liu T,Chen S,Xie X,et al. Soluble TREM-1,as a new ligand for the membrane receptor Robo2,promotes hepatic stellate cells activation and liver fibrosis[J]. J Cell Mol Med,25(24):11113-11127.
[16] Arts R,Joosten L,van der Meer J,et al. TREM-1:intracellular signaling pathways and interaction with pattern recognition receptors[J]. J Leukoc Biol,2013,93(2):209-215.
[17] Xu Z,Hao W,Xu D,et al. Polyene phosphatidylcholine interacting with TLR-2 prevents the synovial inflammation via inactivation of MAPK and NF-κB pathways[J]. Inflammation,2022,45(4):1507-1519.
[18] Hu J,Dusenge M,Ye Q,et al. Role of NOD2 and hepcidin in inflammatory periapical periodontitis[J]. BMC oral health,2022,22(1):263.
[19] Prüfer S,Weber M,Sasca D,et al. Distinct signaling cascades of TREM-1,TLR and NLR in neutrophils and monocytic cells[J]. J Innate Immun,2014,6(3):339-352.
[20] K?kten T,Gibot S,Lepage P,et al. TREM-1 inhibition restores impaired autophagy activity and reduces colitis in mice[J]. J Crohns Colitis,2018,12(2):230-244.
[21] Yang F,Chiu P,Chen Y,et al. TREM-1-dependent M1 macrophage polarization restores intestinal epithelium damaged by DSS-induced colitis by activating IL-22-producing innate lymphoid cells[J]. J Biomed Sci,2019,26(1):46.
[22] Zhang X,Zhao Y,Zhu X,et al. Active vitamin D regulates macrophage M1/M2 phenotypes via the STAT-1-TREM-1 pathway in diabetic nephropathy[J]. J Cell Physiol,2019,234(5):6917-6926.
[23] Wang L,Chen Q,Yu Q,et al. Cigarette smoke extract-treated airway epithelial cells-derived exosomes promote M1 macrophage polarization in chronic obstructive pulmonary disease[J]. Int Immunopharmacol,2021,96:107700.
[24] Xu P,Hong Y,Xie Y,et al. TREM-1 exacerbates neuroinflammatory injury via NLRP3 inflammasome-mediated pyroptosis in experimental subarachnoid hemorrhage[J]. Transl Stroke Res,2021,12(4):643-659.
[25] Wang L,Chen Q,Yu Q,et al. TREM-1 aggravates chronic obstructive pulmonary disease development via activation NLRP3 inflammasome-mediated pyroptosis[J]. Inflamm Res,2021,70(9):971-980.
[26] Li H,Hong F,Pan S,et al. Silencing triggering receptors expressed on myeloid cells-1 impaired the inflammatory response to oxidized low-density lipoprotein in macrophages[J]. Inflammation,2016,39(1):199-208.
[27] Zi Y,Yi-An Y,Bing J,et al. Sirt6-induced autophagy restricted TREM-1-mediated pyroptosis in ox-LDL-treated endothelial cells:relevance to prognostication of patients with acute myocardial infarction[J]. Cell Death Discov,2019,5:88.
[28] Wang H,Gao J,Lu J. Pravastatin improves atherosclerosis in mice with hyperlipidemia by inhibiting TREM-1/DAP12[J]. Eur Rev Med Pharmacol Sci,2018,22(15):4995-5003.
[29] Vázquez C,Costa J,Bomfim L,et al. Oxidized low-density lipoprotein (Ox-LDL) and triggering receptor-expressed myeloid cell (TREM-1) levels are associated with cardiometabolic risk in nonobese,clinically healthy,and young adults[J]. Oxid Med Cell Longev,2019,2019:7306867.
[30] Kutikhin A,Ponasenko A,Khutornaya M,et al. Association of TLR and TREM-1 gene polymorphisms with atherosclerosis severity in a Russian population[J]. Meta Gene,2016,9:76-89.
[31] Rao VH,Rai V,Stoupa S,et al. Data on TREM-1 activation destabilizing carotid plaques[J]. Data Brief,2016,8:230-234.
[32] Rai V,Rao VH,Shao Z,et al. Dendritic cells expressing triggering receptor expressed on myeloid cells-1 correlate with plaque stability in symptomatic and asymptomatic patients with carotid stenosis[J]. PLoS One,2016,11(5):e0154802.
[33] Shiber S,Kliminski V,Orvin K,et al. Elevated plasma soluble triggering receptor expressed on myeloid cells-1 level in patients with acute coronary syndrome (ACS):a biomarker of disease severity and outcome[J]. Mediators Inflamm,2021,2021:8872686.
[34] Wang YK,Tang JN,Shen YL,et al. Prognostic utility of soluble TREM-1 in predicting mortality and cardiovascular events in patients with acute myocardial infarction[J]. J Am Heart Assoc,2018,7(12):e008985.
[35] Kimmoun A,Duarte K,Harjola V,et al. Soluble triggering receptor expressed on myeloid cells-1 is a marker of organ injuries in cardiogenic shock:results from the CardShock Study[J]. Clin Res Cardiol,2022,111(6):604-613.
[36] Ait-Oufella H,Yu M,Kotti S,et al. Plasma and genetic determinants of soluble TREM-1 and major adverse cardiovascular events in a prospective cohort of acute myocardial infarction patients. Results from the FAST-MI 2010 study[J]. Int J Cardiol,2021,344:213-219.
[37] Moussa I,Mohananey D,Saucedo J,et al. Trends and outcomes of restenosis after?coronary stent implantation in?the?United States[J]. J Am Coll Cardiol,2020,76(13):1521-1531.
[38] Wang F,Li C,Ding F,et al. Data on the expression and role of TREM-1 in the development of in-stent restenosis[J]. Data in brief,2018,16:604-607.
[39] Lemarié J,Boufenzer A,Popovic B,et al. Pharmacological inhibition of the triggering receptor expressed on myeloid cells-1 limits reperfusion injury in a porcine model of myocardial infarction[J]. ESC Heart Fail,2015,2(2):90-99.
[40] Weber B,Schuster S,Zysset D,et al. TREM-1 deficiency can attenuate disease severity without affecting pathogen clearance[J]. PLoS Pathog,2014,10(1):e1003900.
相似文献/References:
[1]赵航 汪立杰 金元哲.血流储备分数在冠心病特殊人群中的临床应用进展[J].心血管病学进展,2020,(12):1272.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.012]
ZHAO Hang,WANG L ijie,JIN Yuanzhe.Clinical Application Advances of Fractional Flow Reserve in Special Populations with Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2020,(4):1272.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.012]
[2]方舟 羊镇宇.定量血流分数的临床应用及研究进展[J].心血管病学进展,2021,(3):262.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.017]
FANG ZhouYANG Zhenyu.Clinical Application and Research Progress of Quantitative Flow Ratio[J].Advances in Cardiovascular Diseases,2021,(4):262.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.017]
[3]胥日,羊镇宇.冠状动脉非阻塞性心肌梗死的发病机制[J].心血管病学进展,2021,(2):148.[doi:10.16806/j.cnki.issn.1004-3934.2021.02.014]
XU Ri,YANG Zhenyu.Pathogenesis and Imaging Manifestations of Myocardial Infarction with Non-obstructive Coronary Arteries[J].Advances in Cardiovascular Diseases,2021,(4):148.[doi:10.16806/j.cnki.issn.1004-3934.2021.02.014]
[4]方杰 李春梅 林薿 苏叶 陈丽君 李爽 邓燕 尹立雪 吴志霞.心肌增强多巴酚丁胺负荷超声心动图定量评价冠心病心肌灌注的临床研究[J].心血管病学进展,2021,(8):742.[doi:10.16806/j.cnki.issn.1004-3934.2021.08.017]
FANG Jie,LI Chunmei,LIN Ni,et al.Quantitative Evaluation of Myocardial Perfusion in Coronary Heart Disease by Myocardial Contrast and Dobutamine Stress Echocardiography[J].Advances in Cardiovascular Diseases,2021,(4):742.[doi:10.16806/j.cnki.issn.1004-3934.2021.08.017]
[5]赵润涛 王凡 单冬凯 杨俊杰.CT心肌灌注概述及临床应用进展[J].心血管病学进展,2021,(12):1101.[doi:10.16806/j.cnki.issn.1004-3934.2021.12.011]
ZHAO Runtao WANG Fan SHAN Dongkai?YANG Junjie.CT Myocardial Perfusion and Clinical Application[J].Advances in Cardiovascular Diseases,2021,(4):1101.[doi:10.16806/j.cnki.issn.1004-3934.2021.12.011]
[6]陈杰 常静 石秋月 陈月茗 李鑫 赵宏.钠-葡萄糖共转运蛋白2抑制剂治疗冠心病患者的疗效及作用机制[J].心血管病学进展,2023,(8):704.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.008]
CHEN Jie,CHANG Jing,SHI Qiuyue,et al.Therapeutic Effect and Mechanism of Sodium-Glucose Linked Transporter 2 Inhibitor in Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2023,(4):704.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.008]
[7]纪欣强 单冬凯 王凡 赵润涛 杨俊杰.CT及其衍生技术评价冠状动脉钙化病变的研究进展[J].心血管病学进展,2024,(3):229.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.009]
JI Xinqiang,SHAN Dongkai,WANG Fan,et al.Evaluation of Coronary Artery Calcification Using CT and Its Derivative Techniques[J].Advances in Cardiovascular Diseases,2024,(4):229.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.009]